Melanoma Clinical Trials

Clinical Trials: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy of the PARP Inhibitor ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma

Provides information to potential participants on the following clinical trial: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy of the PARP Inhibitor ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma

Clinical Trials: Phase I/II Study Using a Non-Myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of Allogeneic Tumor-Reactive Lymphocyte Cell Line DMF5 in Metastatic Melanoma

Provides information to potential participants on the following clinical trial: Phase I/II Study Using a Non-Myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of Allogeneic Tumor-Reactive Lymphocyte Cell Line DMF5 in Metastatic Melanoma

Next post in Melanoma Clinical Trials